Get the Stockscreener App
2.24
1.82%
0.04
Ensysce Biosciences Inc stock is traded at $2.24, with a volume of 98,791.
It is up +1.82% in the last 24 hours and up +2.75% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$2.20
Open:
$2.2
24h Volume:
98,791
Relative Volume:
0.06
Market Cap:
$5.31M
Revenue:
-
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.7442
EPS:
-3.01
Net Cash Flow:
$-9.78M
1W Performance:
+5.16%
1M Performance:
+2.75%
6M Performance:
-70.45%
1Y Performance:
-63.84%
1-Day Range:
$2.1766
$2.36
1-Week Range:
$2.10
$2.36
52-Week Range:
$1.62
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.24 | 5.22M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
Has Ensysce Biosciences Inc. Stock Ever Crashed Historical Volatility ReviewTop Performing Stocks - Newser
Why is Ensysce Biosciences Inc. stock attracting strong analyst attentionAccess exclusive market insights for free - jammulinksnews.com
Why Ensysce Biosciences Inc. stock attracts strong analyst attentionFree Top Growth Stock Recommendations - Newser
How volatile is Ensysce Biosciences Inc. stock compared to the marketStay ahead with advanced stock screening tools - jammulinksnews.com
Is Ensysce Biosciences Inc. a good long term investmentHigh-yield investments - PrintWeekIndia
What drives Ensysce Biosciences Inc. stock priceExponential wealth increase - Autocar Professional
Published on: 2025-07-25 08:23:29 - PrintWeekIndia
What analysts say about Ensysce Biosciences Inc. stockHigh-performance investment picks - jammulinksnews.com
When (ENSC) Moves Investors should Listen - news.stocktradersdaily.com
Ensysce Biosciences Inc. Stock Analysis and ForecastUnprecedented profits - jammulinksnews.com
Ensysce Biosciences initiates Phase 3 study of PF614 - TipRanks
FDA-Reviewed Phase 3 Trial Begins: Revolutionary Opioid Promises Pain Relief Without Abuse Risk - Stock Titan
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614A Next-Generation OpioidDesigned to Deliver Powerful Pain Relief and Reduce Abuse - The Globe and Mail
What makes Ensysce Biosciences Inc. stock price move sharplySolid Return Trade Selections - Newser
How Ensysce Biosciences Inc. stock performs during market volatilityHigh Yield Stock Selection - Newser
NAVY(boat pilot token) Tokenomics ExplainedHigh Return Potential - Newser
Where are the Opportunities in (ENSC) - news.stocktradersdaily.com
Travere Therapeutics (NASDAQ:TVTX) and Ensysce Biosciences (NASDAQ:ENSC) Head to Head Comparison - Defense World
FDA-Designated Breakthrough Pain Drug Advances: New Solution to Opioid Overdose Crisis Shows Promise - Stock Titan
(ENSC) Investment Analysis - news.stocktradersdaily.com
Short Interest in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Declines By 71.5% - Defense World
Leading Pain Experts Reveal New Opioid Abuse Prevention Technology at World's Largest Pain Conference - Stock Titan
(ENSC) On The My Stocks Page - news.stocktradersdaily.com
Ensysce Biosciences (NASDAQ:ENSC) Trading 1.7% Higher – Here’s What Happened - Defense World
ensysce biosciences appoints baker tilly as new auditor By Investing.com - Investing.com South Africa
ensysce biosciences appoints baker tilly as new auditor - Investing.com
Ensysce Flat on Receiving Grant - Baystreet.ca
Ensysce Biosciences secures additional $5.3M NIDA grant - Investing.com Australia
Ensysce Biosciences secures additional $5.3M NIDA grant By Investing.com - Investing.com Canada
Ensysce Biosciences (ENSC) Secures $5.3M Grant to Advance Opioid Development | ENSC Stock News - GuruFocus
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):